Obesity and its associated complications comprise some of the world’s most pressing health issues.

We created Verdiva Bio to accelerate the development of differentiated medicines that address the significant unmet medical needs in this space.

Verdiva Bio is developing next-generation medicines with the goal of helping people living with obesity, cardiometabolic diseases, and related conditions achieve better health outcomes through more convenient and patient-friendly treatments.

Our pipeline is built around rationally engineered peptides designed for purpose. Our lead program, VRB-101, is an oral formulation of ecnoglutide, a cAMP-biased, GLP-1 peptide analog, which is currently in Phase 2 clinical development as a once-weekly treatment of obesity. Phase 1 results demonstrated promising efficacy and supported the potential for once-weekly oral dosing, enabled by a proprietary oral absorption enhancer, T2026, designed to support reliable delivery and scalable manufacturing.

Alongside our GLP-1 program, Verdiva is advancing a portfolio of amylin-based product candidates designed to support meaningful weight loss and healthier weight management. These programs include both oral and injectable product candidates, as well as additional undisclosed candidates, expanding our pipeline across complementary mechanisms with the aim to address obesity and related metabolic diseases.